UCBJF:OTCMKTS
UCB
235,44Ā USD
arrow_downward
-1,30%(-3,10) 1d
5 dāoct., 16:00:00 GMT-4 · USD
search
Tots els sĆmbols
| SĆmbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadĆstiques principals per a UCBJF...
Obre
235,44Ā USD
Alt
235,44Ā USD
Baix
235,44Ā USD
CapitalitzaciĆ³ borsĆ ria
39,99Ā kM
Volum mitjĆ
134,00
Volum
41,00
Alt 52 setmanes
345,39Ā USD
Baix 52 setmanes
228,94Ā USD
VersiĆ³ beta
0,58
Accions en circulaciĆ³
194,51Ā M
Nombre d'empleats
9Ā k
Obre
235,44Ā USD
Alt
235,44Ā USD
Baix
235,44Ā USD
CapitalitzaciĆ³ borsĆ ria
39,99Ā kM
Volum mitjĆ
134,00
Volum
41,00
Alt 52 setmanes
345,39Ā USD
Baix 52 setmanes
228,94Ā USD
VersiĆ³ beta
0,58
Accions en circulaciĆ³
194,51Ā M
Nombre d'empleats
9Ā k
NotĆcies
De fonts web i partners de notĆcies
AD HOC NEWS
·
fa 5 hores
UCB stock after-hours at EUR 201.45: minus 1.73 percent versus the prior close
AD HOC NEWS
·
fa 18 hores
ING sets EUR 304 target for UCB stock as Galvokimig advances
AD HOC NEWS
·
fa 1 dia
UCB stock gains 1.49 percent after BIMZELX data
Perfil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of ā¬4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Sobre UCB
Conseller delegatJean-Christophe Tellier
Empleats9Ā k
FundaciĆ³18 de gen. 1928
Seu principal-
Sector-
Lloc webucb.com